FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321019780> ?p ?o ?g. }

• W4321019780 endingPage "1734.e15" @default.
• W4321019780 startingPage "1724" @default.
• W4321019780 abstract "The prevalence of fibrotic diseases and the lack of pharmacologic modalities to effectively treat them impart particular importance to the discovery of novel antifibrotic therapies. The repurposing of drugs with existing mechanisms of action and/or clinical data is a promising approach for the treatment of fibrotic diseases. One paradigm that pervades all fibrotic diseases is the pathological myofibroblast, a collagen-secreting, contractile mesenchymal cell that is responsible for the deposition of fibrotic tissue. In this study, we use a gene expression paradigm characteristic of activated myofibroblasts in combination with the Connectivity Map to select compounds that are predicted to reverse the pathological gene expression signature associated with the myofibroblast and thus contain the potential for use as antifibrotic compounds. We tested a small list of these compounds in a first-pass screen, applying them to fibroblasts, and identified the retinoic acid receptor agonist Ch55 as a potential hit. Further investigation exhibited and elucidated the antifibrotic effects of Ch55 in vitro as well as showing antiscarring activity upon intradermal application in a preclinical rabbit ear hypertrophic scar model. We hope that similar predictions to uncover antiscarring compounds may yield further preclinical and ultimately clinical success. The prevalence of fibrotic diseases and the lack of pharmacologic modalities to effectively treat them impart particular importance to the discovery of novel antifibrotic therapies. The repurposing of drugs with existing mechanisms of action and/or clinical data is a promising approach for the treatment of fibrotic diseases. One paradigm that pervades all fibrotic diseases is the pathological myofibroblast, a collagen-secreting, contractile mesenchymal cell that is responsible for the deposition of fibrotic tissue. In this study, we use a gene expression paradigm characteristic of activated myofibroblasts in combination with the Connectivity Map to select compounds that are predicted to reverse the pathological gene expression signature associated with the myofibroblast and thus contain the potential for use as antifibrotic compounds. We tested a small list of these compounds in a first-pass screen, applying them to fibroblasts, and identified the retinoic acid receptor agonist Ch55 as a potential hit. Further investigation exhibited and elucidated the antifibrotic effects of Ch55 in vitro as well as showing antiscarring activity upon intradermal application in a preclinical rabbit ear hypertrophic scar model. We hope that similar predictions to uncover antiscarring compounds may yield further preclinical and ultimately clinical success. Targeting Myofibroblasts in Dermal Fibrosis: A Retinoid ConnectionJournal of Investigative DermatologyPreviewTissue fibrosis is a pathological condition associated with several chronic inflammatory and autoimmune diseases (Györfi et al., 2018). Hypertrophic scars and keloids develop as a result of aberrant wound healing, induced for example by chronic inflammation and resulting in increased production of extracellular matrix (ECM) by fibroblasts (Kidzeru et al., 2022). Dermal fibrosis may cause cosmetic disfigurement and other complications, such as pain, contracture, and itching (Lee and Jang, 2018). At present, few treatment strategies are available that specifically target the pathogenesis of fibrosis (Györfi et al., 2018). Full-Text PDF" @default.
• W4321019780 created "2023-02-17" @default.
• W4321019780 creator A5053373029 @default.
• W4321019780 creator A5058324393 @default.
• W4321019780 creator A5059430272 @default.
• W4321019780 creator A5081569503 @default.
• W4321019780 creator A5086689278 @default.
• W4321019780 date "2023-09-01" @default.
• W4321019780 modified "2023-10-17" @default.
• W4321019780 title "Prediction and Demonstration of Retinoic Acid Receptor Agonist Ch55 as an Antifibrotic Agent in the Dermis" @default.
• W4321019780 cites W145612403 @default.
• W4321019780 cites W1505584712 @default.
• W4321019780 cites W1539724084 @default.
• W4321019780 cites W1542669094 @default.
• W4321019780 cites W1903138557 @default.
• W4321019780 cites W1978769390 @default.
• W4321019780 cites W1980083057 @default.
• W4321019780 cites W1980325398 @default.
• W4321019780 cites W1989657088 @default.
• W4321019780 cites W1993600060 @default.
• W4321019780 cites W2009358874 @default.
• W4321019780 cites W2020809645 @default.
• W4321019780 cites W2029773580 @default.
• W4321019780 cites W2034032095 @default.
• W4321019780 cites W2035369207 @default.
• W4321019780 cites W2036086603 @default.
• W4321019780 cites W2040476154 @default.
• W4321019780 cites W2047298805 @default.
• W4321019780 cites W2052634171 @default.
• W4321019780 cites W2095206040 @default.
• W4321019780 cites W2104005232 @default.
• W4321019780 cites W2107060225 @default.
• W4321019780 cites W2109554640 @default.
• W4321019780 cites W2109995938 @default.
• W4321019780 cites W2118727460 @default.
• W4321019780 cites W2127749653 @default.
• W4321019780 cites W2131271579 @default.
• W4321019780 cites W2134391212 @default.
• W4321019780 cites W2138207763 @default.
• W4321019780 cites W2138451931 @default.
• W4321019780 cites W2147209470 @default.
• W4321019780 cites W2153426669 @default.
• W4321019780 cites W2161031400 @default.
• W4321019780 cites W2164711772 @default.
• W4321019780 cites W2167063082 @default.
• W4321019780 cites W2171061700 @default.
• W4321019780 cites W2179438025 @default.
• W4321019780 cites W2196955637 @default.
• W4321019780 cites W2310143152 @default.
• W4321019780 cites W2344341820 @default.
• W4321019780 cites W2476542314 @default.
• W4321019780 cites W2612467560 @default.
• W4321019780 cites W2612989432 @default.
• W4321019780 cites W2678080754 @default.
• W4321019780 cites W2758418137 @default.
• W4321019780 cites W2792163150 @default.
• W4321019780 cites W2793027246 @default.
• W4321019780 cites W2794152344 @default.
• W4321019780 cites W2807500957 @default.
• W4321019780 cites W2903048324 @default.
• W4321019780 cites W2917427088 @default.
• W4321019780 cites W2959451193 @default.
• W4321019780 cites W2964849163 @default.
• W4321019780 cites W2987852697 @default.
• W4321019780 cites W3008296460 @default.
• W4321019780 cites W3009593455 @default.
• W4321019780 cites W3022236569 @default.
• W4321019780 cites W3026083210 @default.
• W4321019780 cites W3029928583 @default.
• W4321019780 cites W3042005681 @default.
• W4321019780 cites W3047505759 @default.
• W4321019780 cites W3080707378 @default.
• W4321019780 cites W3094330660 @default.
• W4321019780 cites W3118884673 @default.
• W4321019780 cites W3134022236 @default.
• W4321019780 cites W3163348136 @default.
• W4321019780 cites W4200186978 @default.
• W4321019780 cites W4207053865 @default.
• W4321019780 cites W4280579218 @default.
• W4321019780 cites W4281745556 @default.
• W4321019780 cites W4285030283 @default.
• W4321019780 cites W4292623245 @default.
• W4321019780 cites W4294216483 @default.
• W4321019780 cites W4319066391 @default.
• W4321019780 doi "https://doi.org/10.1016/j.jid.2023.01.024" @default.
• W4321019780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36804965" @default.
• W4321019780 hasPublicationYear "2023" @default.
• W4321019780 type Work @default.
• W4321019780 citedByCount "2" @default.
• W4321019780 countsByYear W43210197802023 @default.
• W4321019780 crossrefType "journal-article" @default.
• W4321019780 hasAuthorship W4321019780A5053373029 @default.
• W4321019780 hasAuthorship W4321019780A5058324393 @default.
• W4321019780 hasAuthorship W4321019780A5059430272 @default.
• W4321019780 hasAuthorship W4321019780A5081569503 @default.
• W4321019780 hasAuthorship W4321019780A5086689278 @default.
• W4321019780 hasConcept C103637391 @default.
• W4321019780 hasConcept C104317684 @default.

• next